Higher Corticosteroid Dose Tied to HBV Reactivation in People With Resolved Infection Higher Corticosteroid Dose Tied to HBV Reactivation in People With Resolved Infection
In people with resolved hepatitis B virus infection, exposure to higher doses of corticosteroids is associated with an increased risk of HBV reactivation and hepatitis flare, according to researchers in China.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 21, 2022 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study, The Lancet Respiratory Medicine
Adults with asthma who had ≥2 oral corticosteroid courses in the past 2 years were at an increased risk of COVID-19 ICU admission or death (adjusted HR 1.27; 95% CI 1.09–1.48); authors suggest those with a recent asthma attack should be considered a priority group for boosters. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 17, 2022 Category: Consumer Health News Source Type: news

WHO recommends two new drugs to treat patients with COVID-19
The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids, says a WHO Guideline Development Group of international experts in The BMJ. (Source: World Pharma News)
Source: World Pharma News - January 17, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

WHO recommends two new drugs to combat COVID-19 infection
The first new drug that is recommended for critical COVID-19 cases is baricitinib, an oral drug that suppresses the immune system when overstimulated. The WHO recommends baricitinib is given... #hospitalization #corticosteroids #monoclonalantibodydrug (Source: Reuters: Health)
Source: Reuters: Health - January 15, 2022 Category: Consumer Health News Source Type: news

ICS Plus LABA Improves Lung Function in School-age Premature Kids ICS Plus LABA Improves Lung Function in School-age Premature Kids
Combining inhaled corticosteroids with long-acting beta-2-receptor agonists improves lung function in school-age children who were born prematurely, according to results of a randomized controlled trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 23, 2021 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

Little Evidence to Support Use of Pricey Repository Corticotropin Little Evidence to Support Use of Pricey Repository Corticotropin
Repository corticotropin costs much more than corticosteroids, but shows little clinical benefit over them, results of a scoping review suggest.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 22, 2021 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Study met all primary and key secondary endpoints Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Global regulatory submissions to occur next year based on data from the Phase 3 clinical trial program INDIANAPOLIS,... Biopharmaceuticals, Dermatology Eli Lilly, lebrikizumab, atopic dermatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 21, 2021 Category: Pharmaceuticals Source Type: news

Do Long-term Low-Dose Steroids Increase Cardiovascular Risk? Do Long-term Low-Dose Steroids Increase Cardiovascular Risk?
Cardiologist Mauricio Wajngarten discusses results of a study looking at the association between cardiovascular risk and the long-term use of corticosteroids in patients with inflammatory disease.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2021 Category: Consumer Health News Tags: Rheumatology Commentary Source Type: news

The first case of fungal endogenous endophthalmitis caused by Aspergillus nidulans : Diagnostic and therapeutic challenge.
Conclusion: Although uncommon, we must consider Aspergillus as the causative organism in apparently immunocompetent patients with history of recent systemic corticosteroids treatment, especially if they suffer a broncopulmonary disorder. Aspergillus is an aggressive organism so a high index of suspicion along with early diagnosis and prompt treatment is the key for better outcomes. We highlight A. nidulans as the causative agent as there are no other reported cases. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 14, 2021 Category: Consumer Health News Source Type: news

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the R...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC)...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also b...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Basel, 07 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra ®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This decision comes just hours after the recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), reflecting the urgent need for Actemra/RoActemra as a potential treatment option during the COVID-19 public health emergency. (Source:...
Source: Roche Investor Update - December 7, 2021 Category: Pharmaceuticals Source Type: news

Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Basel, 07 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra ®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This decision comes just hours after the recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), reflecting the urgent need for Actemra/RoActemra as a potential treatment option during the COVID-19 public health emergency. (Source: Roche Media News)
Source: Roche Media News - December 7, 2021 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Basel, 06 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. A final decision regarding the approval of Actemra/RoActemra is expected from the European Commission in the near future. (Source: Roche Media News)
Source: Roche Media News - December 6, 2021 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Basel, 06 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. A final decision regarding the approval of Actemra/RoActemra is expected from the European Commission in the near future. (Source: Roche Investor Update)
Source: Roche Investor Update - December 6, 2021 Category: Pharmaceuticals Source Type: news

Risk of COVID-19 hospital admission among children aged 517 years with asthma in Scotland: a national incident cohort study, The Lancet Respiratory Medicine
National cohort study (n=752,867) found the risk of COVID-19 hospital admission was markedly increased in children with asthma with previous recent hospital admission (HR 6.40; 95% CI 3.27 –12.53) or ≥2 courses of oral corticosteroids (3.53; 1.87-6.67). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 2, 2021 Category: Consumer Health News Source Type: news

Can Corticosteroids Help in Kids' Eye and Throat Infections? Can Corticosteroids Help in Kids' Eye and Throat Infections?
Prospective studies are needed to clearly identify which patients will benefit.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 30, 2021 Category: Infectious Diseases Tags: Pediatrics News Source Type: news

Asthma Highlights From ACAAI 2021 Asthma Highlights From ACAAI 2021
From ACAAI 2021, Dr Sandhya Khurana reports on advances in asthma, including novel biologic therapies, burden of corticosteroid use, and racial differences in late effects of COVID-19.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

Anti-TNF Therapy Tied to Better Outcomes in IBD Patients With COVID-19 Anti-TNF Therapy Tied to Better Outcomes in IBD Patients With COVID-19
In patients with inflammatory bowel disease who contracted COVID-19 infection, anti-TNF therapies were associated with more favorable outcomes than corticosteroids or mesalamine in a systematic review and analysis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 15, 2021 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Many COVID-19 Survivors Still Can ’t Smell or Taste. Treating Them Isn’t Easy
On the morning after Christmas 2020, Carolyn Hinds woke up and realized she couldn’t smell or taste anything. Other signs of COVID-19, like fever, cough and muscle aches, came in the following days. Those symptoms subsided with time, but her lack of smell and taste did not. To this day, Hinds, 38, can barely smell anything, and her sense of taste remains warped—sweet things leave a strange aftertaste, salty foods upset her stomach and spice makes her lips and tongue burn but tastes like nothing. “These things will mess with you mentally and physically because it changes the way you experience the world,&r...
Source: TIME: Health - November 4, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

New Comprehensive Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
SPRING HOUSE, PENNSYLVANIA, November 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced comprehensive efficacy and safety data from the DISCOVER–2 trial of TREMFYA® (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA).1 Results show a majority of TREMFYA-treated biologic-naïve adult patients with active PsA achieved improvements in joint signs and symptoms (American College of Rheumatology [AC...
Source: Johnson and Johnson - November 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Antipsychotic Effective for Steroid-Induced Psychosis in MS Antipsychotic Effective for Steroid-Induced Psychosis in MS
A popular antipsychotic calms patients with multiple sclerosis (MS) who develop psychiatric distress after taking corticosteroids, a new case review suggests.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 26, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Prediction of outcome based on Trauma and Injury Severity Score, IMPACT and CRASH prognostic models in moderate-to-severe traumatic brain injury in the elderly - Moorthy DGSRK, Rajesh K, Priya SM, Abhinov T, Devendra Prasad KJ.
This study aimed to evaluate the trauma and injury severity score (TRISS), IMPACT (international mission for prognosis and analysis of clinical trials), and CRASH (corticosteroid randomization after significant head injury) prognostic models fo... (Source: SafetyLit)
Source: SafetyLit - October 21, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children with oral corticosteroid-dependent ... Biopharmaceuticals, FDA Regeneron Pharmaceuticals, Dupixent, dupilumab, asthma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 20, 2021 Category: Pharmaceuticals Source Type: news

Do Oral Corticosteroids Drive Fracture Risk in Atopic Eczema? Do Oral Corticosteroids Drive Fracture Risk in Atopic Eczema?
Oral corticosteroids do not appear to be an important driver of major osteoporotic fractures in adults with atopic eczema, according to a large cohort study from the United Kingdom.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 4, 2021 Category: Consumer Health News Tags: Dermatology News Source Type: news

Intranasal Corticosteroids Tied to Less Severe COVID - 19 Outcomes
Findings seen among individuals regularly using steroid nasal sprays before COVID - 19 diagnosis (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 2, 2021 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Allergy, ENT, Pharmacy, Pulmonology, Journal, Source Type: news

Inhaled Corticosteroids and Lung Cancer Risk in COPD Inhaled Corticosteroids and Lung Cancer Risk in COPD
What role might inhaled corticosteroids have in the risk for lung cancer among COPD patients? Is there a protective effect?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 1, 2021 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

Hydroxychloroquine sales spiked almost 100% in Australia at start of Covid pandemic, study finds
There was also a rise in prescriptions for ivermectin being filled, despite no evidence either drug is effective against the virusThe amount of hydroxychloroquine and ivermectin dispensed from Australian pharmacies increased significantly in 2020 as the Covid pandemic took hold, according to new research.Analysis of six publicly subsidised drugs – including hydroxychloroquine, ivermectin, corticosteroids and the common antibiotic azithromycin – found Covid-related changes in prescription patterns in Australia.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 30, 2021 Category: Science Authors: Donna Lu Tags: Health Coronavirus Drugs Medical research Australia news Source Type: news

Featured review: Colchicine for Covid
Is colchicine an effective treatment for people with COVID-19?Colchicine was debated to be a potential treatment option for COVID-19, hoping that the medication ’s anti-inflammatory properties could prevent or reduce a dysregulated immune response.Although there are completed studies without publication and diverse ongoing studies that could change our findings, the current evidence taken from 3 studies is moderate that colchicine makes no difference for people with moderate to severe disease. The safety of the medication remained unclear- given the restricted dosage range and the inconsistent reporting of (serious) ...
Source: Cochrane News and Events - September 30, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Overweight Children With Asthma Less Likely to Respond to Treatment
Higher body mass index tied to poor response to inhaled corticosteroids (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 21, 2021 Category: Respiratory Medicine Tags: Family Medicine, Nursing, Pediatrics, Pharmacy, Pulmonology, Allergy, Conference News, Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Fecal Transplants: a New Treatment for IBD
Linda Ann Sasser has had ulcerative colitis since she was 20, but it wasn’t until May 2019, about 30 years later, that her condition hit a low point: not only did she have a major flare-up of chronic inflammatory bowel disease (IBD), but on top of it, she had Clostridioides difficile (or C. diff), a highly contagious bacterial infection that causes severe diarrhea and inflammation of the colon. “I became really, really sick with bloody diarrhea 30 times a day and chronic stomach pain,” Sasser says. While hospitalized for 12 days, she was given oral steroid medications, which didn’t help, then IV ste...
Source: TIME: Health - September 9, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Disease feature Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How does Lichen Sclerosus et Atrophicus Present?
Discussion Lichen sclerosus et atrophicus (LSA) is a chronic inflammatory disease with a strong autoimmune association. It can occur with other autoimmune diseases. Its specific cause is unknown. It affects females and males of all ages, but especially females 40-60 years. In the pediatric population it affects prepubertal females most often. Treatment includes steroid medications or anti-inflammatory medications. Other treatments may be offered including phototherapy, and much less commonly systemic steroids or immunosuppressive therapy. Circumcision may also be an option for some males. Childhood LSA generally improves b...
Source: PediatricEducation.org - September 6, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Approval supported by data from one of the largest registrational Phase 3 programs in atopic dermatitis evaluating RINVOQ (upadacitinib) monotherapy or with topical corticosteroids[1] RINVOQ met all primary and secondary endpoints, demonstrating rapid a... Biopharmaceuticals, Dermatology, Regulatory AbbVie, RINVOQ, upadacitinib, atopic dermatitis, JAK inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 24, 2021 Category: Pharmaceuticals Source Type: news

Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks Upadacitinib Effective and Safe in Atopic Dermatitis at 52 Weeks
The JAK inhibitor shows efficacy and safety when used in combination with topical corticosteroids, and showed superiority in a head-to-head comparison with dupilumab.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 19, 2021 Category: Dermatology Tags: Allergy & Clinical Immunology News Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Continuous Corticosteroids Best for Mild, Well-Controlled, Asthma? Continuous Corticosteroids Best for Mild, Well-Controlled, Asthma?
Discontinuing ICS may make sense for some patients with well-controlled asthma, but some patients with mild and well-controlled disease may fare better by continuing treatment, according to a study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 12, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 10th August 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. We are continually monitoring the evidence and updating the guideline as new information emerges. Priority areas for update include recommendations on heparins. On 10 August 2021, we corrected an error in the practical info section of the recommendations on corticosteroids. The dose of prednisolone for c...
Source: Current Awareness Service for Health (CASH) - August 12, 2021 Category: Consumer Health News Source Type: news

Sjogren's Syndrome With Nervous System Injury and Cryptococcosis Sjogren's Syndrome With Nervous System Injury and Cryptococcosis
This case details a rare form of neural involvement in Sjogren's syndrome, combined with pulmonary and osseous cryptococcosis due to long-term use of high-dose corticosteroids and immunosuppressants.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Waiting 3 Months After Corticosteroid Injections for TKA Waiting 3 Months After Corticosteroid Injections for TKA
When is it safe to administer corticosteroid injections in TKA patients? A new study aims to determine the optimal timing.Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 11, 2021 Category: Surgery Tags: Orthopaedics Journal Article Source Type: news

Are corticosteroids given orally or by injection an effective treatment for people with COVID-19?
 Are corticosteroids (anti-inflammatory medicines) given orally or by injection an effective treatment for people with COVID-19?Key messagesCorticosteroids (anti-inflammatory medicines) given orally or by injection (systemic) are probably effective treatments for people hospitalised with COVID-19.   The authors don’t know whether they cause unwanted effects. The authorsdon ’t know which systemic corticosteroid is the most effective. They found no evidence about people without symptoms or with mild COVID-19 who were not hospitalised. They found 42 ongoing studies and 16 completed studies that...
Source: Cochrane News and Events - August 10, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news

Short-Acting Beta Agonist Overuse'a Global Public Health Issue'Short-Acting Beta Agonist Overuse'a Global Public Health Issue '
Overreliance on SABAs and underuse of inhaled corticosteroids are associated with increased risk of exacerbations and asthma-related death.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news